

Special Issue

Progress in Influenza Vaccine Research

Message from the Guest Editor

The impact of vaccines on the course of COVID-19 pandemic has brought to light the importance of vaccine research in pandemic preparedness. Current influenza vaccine will not be able to provide any protection in the case of influenza pandemic. Thus, there is a need for universal influenza vaccine that can induce broader and long lasting immune response to protect against all circulating and emerging influenza virus variants. To develop such a vaccine a deeper understanding of correlates of protection against influenza virus is required. In addition, improved vaccine production processes are also required to make enough vaccine doses quickly. We also need improved vaccines against avian and swine influenza virus to protect our livestock and to minimize chances of human exposure to these influenza viruses. Additionally, there is requirement for development of improved model systems for rapid testing and comparison of novel vaccines. Hopefully, we will be better prepared when a new influenza pandemic arrives. The special issue of Vaccines will cover all these aspects of influenza vaccine research. In this Special Issue, original research articles and reviews are welcome

Guest Editor

Dr. Amit Gaba

Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

Deadline for manuscript submissions

closed (31 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/133014

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).